Patient Characteristics
| Characteristic . | GIS BMT . | HIR BMT . |
|---|---|---|
| Sex (F/M) | 18/10 | 12/14 |
| Median age at BMT, yr (range) | 1.8 (0.4-4.6) | 1.9 (0.7-7.9) |
| Bone marrow donor enzyme status (n) | ||
| Homozygous normal/heterozygous carrier | 15/13 | 3/23 |
| Bone marrow manipulation (n) | ||
| T-lymphocyte depletion | 0 | 14 |
| T10B9 | 11 | |
| Antibody + complement | 1 | |
| Soybean agglutinin + sheep RBC rosetting | 2 | |
| No T-lymphocyte depletion | 26 | 11 |
| Not assessable | 2 | 0 |
| Unknown | 0 | 1 |
| Degree of HLA matching (n) | ||
| 6 of 6 | 28 | 5 |
| 5 of 6 | 0 | 8 |
| 4 of 6 | 0 | 8 |
| 3 of 6 | 0 | 4 |
| Unknown | 0 | 1 |
| Preparative therapy (n) | ||
| BU/cy | 23 | 8 |
| BU/cy + TBI | 1 | 0 |
| Ara-C/cy + TBI | 0 | 12 |
| cy + TBI | 1 | 3 |
| BU/cy + TBI | 1 | 1 |
| Not assessable | 2 | 0 |
| VP-16/Ara-C/cy + TBI | 0 | 1 |
| Unknown | 0 | 1 |
| GVHD prophylaxis (n) | ||
| Cyclosporin/corticosteroid ± ATG | 11 | 6 |
| Cyclosporin/methotrexate | 8 | 3 |
| Anti–CD-5/corticosteroid | 0 | 10 |
| Methotrexate/corticosteroid ± ATG | 6 | 0 |
| ATG or ALG/corticosteroid | 0 | 2 |
| None | 1 | 1 |
| Other | 0 | 3 |
| Not assessable | 2 | 0 |
| Unknown | 0 | 1 |
| Median bone marrow cell dose (range)-150 | 3.6 (1.9-10.3) | 2.9 (0.6-5.1) |
| Characteristic . | GIS BMT . | HIR BMT . |
|---|---|---|
| Sex (F/M) | 18/10 | 12/14 |
| Median age at BMT, yr (range) | 1.8 (0.4-4.6) | 1.9 (0.7-7.9) |
| Bone marrow donor enzyme status (n) | ||
| Homozygous normal/heterozygous carrier | 15/13 | 3/23 |
| Bone marrow manipulation (n) | ||
| T-lymphocyte depletion | 0 | 14 |
| T10B9 | 11 | |
| Antibody + complement | 1 | |
| Soybean agglutinin + sheep RBC rosetting | 2 | |
| No T-lymphocyte depletion | 26 | 11 |
| Not assessable | 2 | 0 |
| Unknown | 0 | 1 |
| Degree of HLA matching (n) | ||
| 6 of 6 | 28 | 5 |
| 5 of 6 | 0 | 8 |
| 4 of 6 | 0 | 8 |
| 3 of 6 | 0 | 4 |
| Unknown | 0 | 1 |
| Preparative therapy (n) | ||
| BU/cy | 23 | 8 |
| BU/cy + TBI | 1 | 0 |
| Ara-C/cy + TBI | 0 | 12 |
| cy + TBI | 1 | 3 |
| BU/cy + TBI | 1 | 1 |
| Not assessable | 2 | 0 |
| VP-16/Ara-C/cy + TBI | 0 | 1 |
| Unknown | 0 | 1 |
| GVHD prophylaxis (n) | ||
| Cyclosporin/corticosteroid ± ATG | 11 | 6 |
| Cyclosporin/methotrexate | 8 | 3 |
| Anti–CD-5/corticosteroid | 0 | 10 |
| Methotrexate/corticosteroid ± ATG | 6 | 0 |
| ATG or ALG/corticosteroid | 0 | 2 |
| None | 1 | 1 |
| Other | 0 | 3 |
| Not assessable | 2 | 0 |
| Unknown | 0 | 1 |
| Median bone marrow cell dose (range)-150 | 3.6 (1.9-10.3) | 2.9 (0.6-5.1) |
Abbreviations: T10B9, monoclonal antibody T10B9.1-31A and rabbit serum complement; antibody + complement, anti-CD2 antibody and rabbit serum complement; soybean agglutinin + sheep RBC rosetting, soybean agglutination and sheep RBC rosetting; BU/cy, busulfan (range, 12 to 25 mg/kg in divided doses every 6 hours over 4 days)/cyclophosphamide (range, 200 to 240 mg/kg in 4 divided doses over 4 days) with or without antithymocyte globulin (ATG); TBI, total-body irradiation (20 patients, 300 to 1,400 cGy; single dose, 3 patients); Ara-C/cy + TBI, cytosine arabinoside (18 g/m2in 6 divided doses over 3 days)/cy (range, 90 to 100 mg/kg in 2 divided doses over 2 days) and TBI; cy + TBI,cy (120 mg/m2 in 2 divided doses over 2 days) and TBI; BU/cy + TBI, reduced-dose BU (320 mg/m2 in divided doses every 6 hours over 2 days)/reduced-dose cy (120 mg/kg in 2 divided doses over 2 days) and TBI; VP-16/Ara-C/cy + TBI, etoposide (500 mg/m2 in 2 divided doses over 2 days)/Ara-C (18 g/m2 in 6 divided doses over 3 days)/cy (90 mg/kg in 2 divided doses over 2 days) and TBI (TBI dosage range and patient number: 300 cGy, n = 1; 720 to 850 cGy, n = 3; 1,200 cGy, n = 3; 1,400 cGy, n = 11; unknown, n = 2); anti–CD-5/corticosteroid, anti-CD5 ricin A chain–conjugated immunotoxin and corticosteroid; ALG, antilymphocyte globulin.
× 108 nucleated cells/kg recipient body weight.